Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover Emerging Technologies Driving the Future of Global Markets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Cosmos Health Inc COSM

Healthcare Medical Distribution
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and... see more

Recent & Breaking News (NDAQ:COSM)

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

ACCESS Newswire 4 days ago

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

ACCESS Newswire 6 days ago

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

ACCESS Newswire 7 days ago

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

ACCESS Newswire 10 days ago

Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness

ACCESS Newswire 12 days ago

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

ACCESS Newswire April 30, 2026

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

ACCESS Newswire April 21, 2026

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

ACCESS Newswire April 20, 2026

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

ACCESS Newswire April 17, 2026

Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%

ACCESS Newswire April 16, 2026

Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments

ACCESS Newswire April 15, 2026

Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units

ACCESS Newswire April 13, 2026

Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months

ACCESS Newswire April 10, 2026

Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction

ACCESS Newswire April 8, 2026

Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets

ACCESS Newswire April 1, 2026

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

GlobeNewswire March 19, 2026

Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

GlobeNewswire March 11, 2026

Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

GlobeNewswire March 10, 2026

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

GlobeNewswire February 24, 2026

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

GlobeNewswire February 19, 2026

Podcasts